Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL

An update on the EPCORE NHL-1 trialПодробнее

EPCORE NHL-1 subgroup analyses: epcoritamab monotherapy in patients with R/R LBCLПодробнее

Early results from EPCORE CLL-1 trial: subcutaneous epcoritamab in patients with Richter’s syndromeПодробнее

EPCORE NHL-2: epcoritamab with rituximab and lenalidomide in newly diagnosed and R/R FLПодробнее

EPCORE NHL-1: two and a half year follow-up of epcoritamab in DLBCLПодробнее

Phase II study of epcoritamab in R/R LBCLПодробнее

Subcutaneous epcoritamab in R/R B-cell NHLПодробнее

EPCORE NHL-1: health-related QoL in patients with R/R LBCL treated with subcutaneous epcoritamabПодробнее

Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular LymphomaПодробнее

Reducing CRS following epcoritamab in R/R FL: insights from an optimization cohort of EPCORE NHL-1Подробнее

Updated results from EPCORE NHL-2: epcoritamab plus GemOx in patients with R/R DLBCLПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

Epcoritamab monotherapy and combinations in R/R CLL and Richter’s syndromeПодробнее

Epcoritamab + R-Mini-CHOP in previously untreated DLBCL: insights from EPCORE NHL-2Подробнее

New DLBCL Clinical Trial: Epcoritamab for Diffuse Large B-Cell LymphomaПодробнее

Epcoritamab in R/R FL: pooled efficacy data from EPCORE NHL-1Подробнее

Results of Phase I/II study of epcoritamab+R-DHAX/C in patients with R/R DLBCL eligible for autoSCTПодробнее

Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MDПодробнее